Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer

Current Medicinal Chemistry

Volumn 19, Issue 6, 2012, Pages 856-870

  Barinka C ^a   Rojas, C ^b   Slusher, B ^b   Pomper, M ^c  

^a INSTITUTE OF BIOTECHNOLOGY   (Czech Republic)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Glutamate excitotoxicity; Metalloprotease; N acetylaspartylglutamate; Prostate cancer; Prostate specific membrane antigen

Indexed keywords

2 (PHOSPHONOMETHYL)PENTANEDIOIC ACID; ACTINIUM 225; BISMUTH 213; CAPROMAB PENDETIDE IN 111; CARBON 11; FLUORINE 18; GALLIUM 68; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II INHIBITOR; GLUTAMIC ACID; GPI 5232; IODINE 131; LAMOTRIGINE; LUTETIUM 177; MONOCLONAL ANTIBODY J591; NEUROTRANSMITTER; PHOSPHINIC ACID DERIVATIVE; PHOSPHONIC ACID DERIVATIVE; RILUZOLE; TECHNETIUM 99M; THIOL REAGENT; UNCLASSIFIED DRUG; UREA DERIVATIVE; YTTRIUM 90; ZJ 11; ZJ 17; ZJ 43;

AMYOTROPHIC LATERAL SCLEROSIS; BRAIN INJURY; COCAINE DEPENDENCE; DIABETIC NEUROPATHY; DIAGNOSTIC IMAGING; DRUG BIOAVAILABILITY; DRUG DEPENDENCE; DRUG PENETRATION; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG TARGETING; ENZYME DEGRADATION; ENZYME LOCALIZATION; EPILEPSY; EXCITOTOXICITY; HUMAN; HYDROLYSIS; INFLAMMATION; ISCHEMIA; MOTOR NEURON DISEASE; NERVOUS SYSTEM; NEUROLOGIC DISEASE; NEUROPATHIC PAIN; NEUROPROTECTION; NEUROTOXICITY; PAIN; PERIPHERAL NEUROPATHY; PROSTATE CANCER; PROSTATE CARCINOMA; PROTEIN EXPRESSION; REVIEW; SCHIZOPHRENIA; SEIZURE; SIGNAL TRANSDUCTION; SPINAL CORD INJURY; STROKE; TRAUMATIC BRAIN INJURY;

ANIMALS; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; MALE; NERVOUS SYSTEM DISEASES; PROSTATIC NEOPLASMS;

EID: 84857589525     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712799034888     Document Type: Review

References (211)

1. Anilkumar, G.; Rajasekaran, S. A.; Wang, S.; Hankinson, O.; Bander, N. H.; Rajasekaran, A. K. Prostate-specific membrane antigen association with filamin A modulates its internalization and NAALADase activity. Cancer Res., 2003, 63, 2645-2648. (Pubitemid 36605208)
2. Anilkumar, G.; Barwe, S. P.; Christiansen, J. J.; Rajasekaran, S. A.; Kohn, D. B.; Rajasekaran, A. K. Association of prostate-specific membrane antigen with caveolin-1 and its caveolae-dependent internalization in microvascular endothelial cells: Implications for targeting to tumor vasculature. Microvasc. Res., 2006, 72, 54-61. (Pubitemid 44118386)
3. Goodman, O.B., Jr.; Barwe, S. P.; Ritter, B.; McPherson, P. S.; Vasko, A. J.; Keen, J. H.; Nanus, D. M.; Bander, N. H.; Rajasekaran, A. K. Interaction of prostate specific membrane antigen with clathrin and the adaptor protein complex-2. Int. J. Oncol., 2007, 31, 1199-1203.
4. Rajasekaran, S.A.; Anilkumar, G.; Oshima, E.; Bowie, J. U.; Liu, H.; Heston, W.; Bander, N. H.; Rajasekaran, A. K. A novel cytoplasmic tail MXXXL motif mediates the internalization of prostate-specific membrane antigen. Mol. Biol. Cell, 2003, 14, 4835-4845. (Pubitemid 37484800)
5. Liu, H.; Rajasekaran, A. K.; Moy, P.; Xia, Y.; Kim, S.; Navarro, V.; Rahmati, R.; Bander, N. H. Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res., 1998, 58, 4055-4060. (Pubitemid 28440554)
6. Schulke, N.; Varlamova, O. A.; Donovan, G. P.; Ma, D.; Gardner, J. P.; Morrissey, D. M.; Arrigale, R. R.; Zhan, C.; Chodera, A. J.; Surowitz, K. G.; Maddon, P. J.; Heston, W. D.; Olson, W. C. The homodimer of prostatespecific membrane antigen is a functional target for cancer therapy. Proc. Natl. Acad. Sci. U. S. A, 2003, 100, 12590-12595. (Pubitemid 37339943)
7. Mesters, J.R.; Barinka, C.; Li, W.; Tsukamoto, T.; Majer, P.; Slusher, B. S.; Konvalinka, J.; Hilgenfeld, R. Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer. EMBO J., 2006, 25, 1375-1384.
8. Barinka, C.; Rinnova, M.; Sacha, P.; Rojas, C.; Majer, P.; Slusher, B. S.; Konvalinka, J. Substrate specificity, inhibition and enzymological analysis of recombinant human glutamate carboxypeptidase II. J. Neurochem., 2002, 80, 477-487. (Pubitemid 36383031)
9. Barinka, C.; Sacha, P.; Sklenar, J.; Man, P.; Bezouska, K.; Slusher, B. S.; Konvalinka, J. Identification of the N-glycosylation sites on glutamate carboxypeptidase II necessary for proteolytic activity. Protein Sci., 2004, 13, 1627-1635. (Pubitemid 38669250)
10. Castelletti, D.; Fracasso, G.; Alfalah, M.; Cingarlini, S.; Colombatti, M.; Naim, H. Y. Apical transport and folding of prostate-specific membrane antigen occurs independent of glycan processing. J. Biol. Chem., 2006, 281, 3505-3512. (Pubitemid 43845966)
11. Ghosh, A. and Heston, W. D. Effect of carbohydrate moieties on the folate hydrolysis activity of the prostate specific membrane antigen. Prostate, 2003, 57, 140-151. (Pubitemid 37204495)
12. Holmes, E.H.; Greene, T. G.; Tino, W. T.; Boynton, A. L.; Aldape, H. C.; Misrock, S. L.; Murphy, G. P. Analysis of glycosylation of prostate-specific membrane antigen derived from LNCaP cells, prostatic carcinoma tumors, and serum from prostate cancer patients. Prostate Suppl, 1996, 7, 25-29. (Pubitemid 26412173)
13. Castelletti, D.; Alfalah, M.; Heine, M.; Hein, Z.; Schmitte, R.; Fracasso, G.; Colombatti, M.; Naim, H. Y. Different glycoforms of prostate-specific membrane antigen are intracellularly transported through their association with distinct detergent-resistant membranes. Biochem. J., 2008, 409, 149-157.
14. Christiansen, J.J.; Rajasekaran, S. A.; Inge, L.; Cheng, L.; Anilkumar, G.; Bander, N. H.; Rajasekaran, A. K. N-glycosylation and microtubule integrity are involved in apical targeting of prostate-specific membrane antigen: Implications for immunotherapy. Mol. Cancer Ther., 2005, 4, 704-714. (Pubitemid 40767114)
15. Davis, M.I.; Bennett, M. J.; Thomas, L. M.; Bjorkman, P. J. Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase. Proc. Natl. Acad. Sci. U. S. A, 2005, 102, 5981-5986. (Pubitemid 40594241)
16. Lawrence, C.M.; Ray, S.; Babyonyshev, M.; Galluser, R.; Borhani, D. W.; Harrison, S. C. Crystal structure of the ectodomain of human transferrin receptor. Science, 1999, 286, 779-782.
17. Klusak, V.; Barinka, C.; Plechanovova, A.; Mlcochova, P.; Konvalinka, J.; Rulisek, L.; Lubkowski, J. Reaction mechanism of glutamate carboxypeptidase II revealed by mutagenesis, X-ray crystallography, and computational methods. Biochemistry, 2009, 48, 4126-4138.
18. Speno, H.S.; Luthi-Carter, R.; Macias, W. L.; Valentine, S. L.; Joshi, A. R.; Coyle, J. T. Site-directed mutagenesis of predicted active site residues in glutamate carboxypeptidase II. Mol. Pharmacol., 1999, 55, 179-185. (Pubitemid 29042536)
19. Barinka, C.; Rovenska, M.; Mlcochova, P.; Hlouchova, K.; Plechanovova, A.; Majer, P.; Tsukamoto, T.; Slusher, B. S.; Konvalinka, J.; Lubkowski, J. Structural insight into the pharmacophore pocket of human glutamate carboxypeptidase II. J. Med. Chem., 2007, 50, 3267-3273. (Pubitemid 47065975)
20. Mesters, J.R.; Henning, K.; Hilgenfeld, R. Human glutamate carboxypeptidase II inhibition: Structures of GCPII in complex with two potent inhibitors, quisqualate and 2-PMPA. Acta Crystallogr. D. Biol. Crystallogr., 2007, 63, 508-513. (Pubitemid 46465946)
21. Wang, H.; Byun, Y.; Barinka, C.; Pullambhatla, M.; Bhang, H. E.; Fox, J. J.; Lubkowski, J.; Mease, R. C.; Pomper, M. G. Bioisosterism of urea-based GCPII inhibitors: Synthesis and structure-Activity relationship studies. Bioorg. Med. Chem. Lett., 2010, 20, 392-397.
22. Hlouchova, K.; Barinka, C.; Klusak, V.; Sacha, P.; Mlcochova, P.; Majer, P.; Rulisek, L.; Konvalinka, J. Biochemical characterization of human glutamate carboxypeptidase III. J. Neurochem., 2007, 101, 682-696. (Pubitemid 46633308)
23. Majer, P.; Hin, B.; Stoermer, D.; Adams, J.; Xu, W.; Duvall, B. R.; Delahanty, G.; Liu, Q.; Stathis, M. J.; Wozniak, K. M.; Slusher, B. S.; Tsukamoto, T. Structural Optimization of Thiol-Based Inhibitors of Glutamate Carboxypeptidase II by Modification of the P1' Side Chain. J. Med.Chem., 2006, 49, 2876-2885.
24. Barinka, C.; Hlouchova, K.; Rovenska, M.; Majer, P.; Dauter, M.; Hin, N.; Ko, Y. S.; Tsukamoto, T.; Slusher, B. S.; Konvalinka, J.; Lubkowski, J. Structural basis of interactions between human glutamate carboxypeptidase II and its substrate analogs. J. Mol. Biol., 2008, 376, 1438-1450.
25. Jackson, P.F.; Tays, K. L.; Maclin, K. M.; Ko, Y. S.; Li, W.; Vitharana, D.; Tsukamoto, T.; Stoermer, D.; Lu, X. C.; Wozniak, K.; Slusher, B. S. Design and pharmacological activity of phosphinic acid based NAALADase inhibitors. J. Med.Chem., 2001, 44, 4170-4175. (Pubitemid 33095323)
26. Kozikowski, A.P.; Zhang, J.; Nan, F.; Petukhov, P. A.; Grajkowska, E.; Wroblewski, J. T.; Yamamoto, T.; Bzdega, T.; Wroblewska, B.; Neale, J. H. Synthesis of urea-based inhibitors as active site probes of glutamate carboxypeptidase II: Efficacy as analgesic agents. J. Med.Chem., 2004, 47, 1729-1738. (Pubitemid 38380916)
27. Liu, T.; Toriyabe, Y.; Kazak, M.; Berkman, C. E. Pseudoirreversible inhibition of prostate-specific membrane antigen by phosphoramidate peptidomimetics. Biochemistry, 2008, 47, 12658-12660.
28. Maung, J.; Mallari, J. P.; Girtsman, T. A.; Wu, L. Y.; Rowley, J. A.; Santiago, N. M.; Brunelle, A. N.; Berkman, C. E. Probing for a hydrophobic a binding register in prostate-specific membrane antigen with phenylalkylphosphonamidates. Bioorg Med Chem, 2004, 12, 4969-4979. (Pubitemid 39164405)
29. Tsukamoto, T.; Wozniak, K. M.; Slusher, B. S. Progress in the discovery and development of glutamate carboxypeptidase II inhibitors. Drug Discov Today, 2007, 12, 767-776. (Pubitemid 47362787)
30. Zhang, A.X.; Murelli, R. P.; Barinka, C.; Michel, J.; Cocleaza, A.; Jorgensen, W. L.; Lubkowski, J.; Spiegel, D. A. A remote arene-binding site on prostate specific membrane antigen revealed by antibody-recruiting small molecules. J. Am. Chem. Soc., 2010, 132, 12711-12716.
31. Zhou, J.; Neale, J. H.; Pomper, M. G.; Kozikowski, A. P. NAAG peptidase inhibitors and their potential for diagnosis and therapy. Nat. Rev. Drug Discov., 2005, 4, 1015-1026.
32. Horoszewicz, J.S.; Kawinski, E.; Murphy, G. P. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res., 1987, 7, 927-935. (Pubitemid 18036141)
33. Carter, R.E.; Feldman, A. R.; Coyle, J. T. Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase. Proc. Natl. Acad. Sci. U. S. A, 1996, 93, 749-753. (Pubitemid 26041162)
34. Kinoshita, Y.; Kuratsukuri, K.; Landas, S.; Imaida, K.; Rovito, P. M., Jr.; Wang, C. Y.; Haas, G. P. Expression of prostate-specific membrane antigen in normal and malignant human tissues. World J. Surg., 2006, 30, 628-636.
35. Mhawech-Fauceglia, P.; Zhang, S.; Terracciano, L.; Sauter, G.; Chadhuri, A.; Herrmann, F. R.; Penetrante, R. Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: An immunohistochemical study using mutiple tumour tissue microarray technique. Histopathology, 2007, 50, 472-483. (Pubitemid 46328190)
36. Rovenska, M.; Hlouchova, K.; Sacha, P.; Mlcochova, P.; Horak, V.; Zamecnik, J.; Barinka, C.; Konvalinka, J. Tissue expression and enzymologic characterization of human prostate specific membrane antigen and its rat and pig orthologs. Prostate, 2008, 68, 171-182. (Pubitemid 351186229)
37. Sacha, P.; Zamecnik, J.; Barinka, C.; Hlouchova, K.; Vicha, A.; Mlcochova, P.; Hilgert, I.; Eckschlager, T.; Konvalinka, J. Expression of glutamate carboxypeptidase II in human brain. Neuroscience, 2007, 144, 1361-1372. (Pubitemid 46123795)
38. Silver, D.A.; Pellicer, I.; Fair, W. R.; Heston, W. D.; Cordon-Cardo, C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin. Cancer Res., 1997, 3, 81-85. (Pubitemid 27079448)
39. Sokoloff, R.L.; Norton, K. C.; Gasior, C. L.; Marker, K. M.; Grauer, L. S. A dual-monoclonal sandwich assay for prostate-specific membrane antigen: Levels in tissues, seminal fluid and urine. Prostate, 2000, 43, 150-157. (Pubitemid 30220618)
40. Troyer, J.K.; Beckett, M. L.; Wright, G. L., Jr. Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int. J. Cancer, 1995, 62, 552-558.
41. Bostwick, D.G.; Pacelli, A.; Blute, M.; Roche, P.; Murphy, G. P. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: A study of 184 cases. Cancer, 1998, 82, 2256-2261. (Pubitemid 28240834)
42. Berger, U.V.; Carter, R. E.; McKee, M.; Coyle, J. T. N-Acetylated alphalinked acidic dipeptidase is expressed by non-myelinating Schwann cells in the peripheral nervous system. J. Neurocytol., 1995, 24, 99-109.
43. Chang, S.S.; Reuter, V. E.; Heston, W. D.; Bander, N. H.; Grauer, L. S.; Gaudin, P. B. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-Associated neovasculature. Cancer Res., 1999, 59, 3192-3198. (Pubitemid 29316022)
44. Lopes, A.D.; Davis, W. L.; Rosenstraus, M. J.; Uveges, A. J.; Gilman, S. C. Immunohistochemical and pharmacokinetic characterization of the sitespecific immunoconjugate CYT-356 derived from antiprostate monoclonal antibody 7E11-C5. Cancer Res., 1990, 50, 6423-6429. (Pubitemid 20323709)
45. Bander, N.H. Technology insight: Monoclonal antibody imaging of prostate cancer. Nat. Clin. Pract. Urol., 2006, 3, 216-225.
46. Chen, Y.; Dhara, S.; Banerjee, S. R.; Byun, Y.; Pullambhatla, M.; Mease, R. C.; Pomper, M. G. A low molecular weight PSMA-based fluorescent imaging agent for cancer. Biochem. Biophys. Res. Commun., 2009, 390, 624-629.
47. David, K.A.; Milowsky, M. I.; Kostakoglu, L.; Vallabhajosula, S.; Goldsmith, S. J.; Nanus, D. M.; Bander, N. H. Clinical utility of radiolabeled monoclonal antibodies in prostate cancer. Clin. Genitourin. Cancer, 2006, 4, 249-256. (Pubitemid 43779881)
48. Foss, C.A.; Mease, R. C.; Fan, H.; Wang, Y.; Ravert, H. T.; Dannals, R. F.; Olszewski, R. T.; Heston, W. D.; Kozikowski, A. P.; Pomper, M. G. Radiolabeled small-molecule ligands for prostate-specific membrane antigen: In vivo imaging in experimental models of prostate cancer. Clin. Cancer Res., 2005, 11, 4022-4028. (Pubitemid 40791565)
49. Mease, R.C.; Dusich, C. L.; Foss, C. A.; Ravert, H. T.; Dannals, R. F.; Seidel, J.; Prideaux, A.; Fox, J. J.; Sgouros, G.; Kozikowski, A. P.; Pomper, M. G. N-[N-[(S)-1,3-Dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-L cysteine, [18F]DCFBC: A new imaging probe for prostate cancer. Clin. Cancer Res., 2008, 14, 3036-3043.
50. Gala, J.L.; Loric, S.; Guiot, Y.; Denmeade, S. R.; Gady, A.; Brasseur, F.; Heusterspreute, M.; Eschwege, P.; De, N. P.; Van, C. P.; Tombal, B. Expression of prostate-specific membrane antigen in transitional cell carcinoma of the bladder: Prognostic value? Clin. Cancer Res., 2000, 6, 4049-4054.
51. Haffner, M.C.; Kronberger, I. E.; Ross, J. S.; Sheehan, C. E.; Zitt, M.; Muhlmann, G.; Ofner, D.; Zelger, B.; Ensinger, C.; Yang, X. J.; Geley, S.; Margreiter, R.; Bander, N. H. Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers. Hum. Pathol., 2009, 40, 1754-1761.
52. Wang, W.; Tavora, F.; Sharma, R.; Eisenberger, M.; Netto, G. J. PSMA expression in Schwannoma: A potential clinical mimicker of metastatic prostate carcinoma. Urol. Oncol., 2009, 27, 525-528.
53. Chang, S.S.; O'Keefe, D. S.; Bacich, D. J.; Reuter, V. E.; Heston, W. D.; Gaudin, P. B. Prostate-specific membrane antigen is produced in tumorassociated neovasculature. Clin. Cancer Res., 1999, 5, 2674-2681. (Pubitemid 29493938)
54. Milowsky, M.I.; Nanus, D. M.; Kostakoglu, L.; Sheehan, C. E.; Vallabhajosula, S.; Goldsmith, S. J.; Ross, J. S.; Bander, N. H. Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. J. Clin. Oncol., 2007, 25, 540-547. (Pubitemid 350002961)
55. Morris, M.J.; Pandit-Taskar, N.; Divgi, C. R.; Bender, S.; O'Donoghue, J. A.; Nacca, A.; Smith-Jones, P.; Schwartz, L.; Slovin, S.; Finn, R.; Larson, S.; Scher, H. I. Phase I evaluation of J591 as a vascular targeting agent in progressive solid tumors. Clin. Cancer Res., 2007, 13, 2707-2713. (Pubitemid 46788039)
56. Slusher, B.S. and Jackson, P. F. Methods of cancer treatment using NAALADase inhibitors. U.S. Patent 5,804,602, September 8, 1998.
57. Slusher, B.S. and Lapidus, R. G. Pharmaceutical compositions and methods of inhibiting angiogenesis using NAALADase inhibitors. U.S. Patent 2003/0064912 A1, April 3, 2003.
58. Yao, V. and Bacich, D. J. Prostate specific membrane antigen (PSMA) expression gives prostate cancer cells a growth advantage in a physiologically relevant folate environment in vitro. Prostate, 2006, 66, 867-875.
59. Yao, V.; Berkman, C. E.; Choi, J. K.; O'Keefe, D. S.; Bacich, D. J. Expression of prostate-specific membrane antigen (PSMA), increases cell folate uptake and proliferation and suggests a novel role for PSMA in the uptake of the non-polyglutamated folate, folic acid. Prostate, 2010, 70, 305-316.
60. Conway, R.E.; Petrovic, N.; Li, Z.; Heston, W.; Wu, D.; Shapiro, L. H. Prostate-specific membrane antigen regulates angiogenesis by modulating integrin signal transduction. Mol. Cell Biol., 2006, 26, 5310-5324. (Pubitemid 44036201)
61. Yao, V.; Parwani, A.; Maier, C.; Heston, W. D.; Bacich, D. J. Moderate expression of prostate-specific membrane antigen, a tissue differentiation antigen and folate hydrolase, facilitates prostate carcinogenesis. Cancer Res., 2008, 68, 9070-9077.
62. Ghosh, A.; Wang, X.; Klein, E.; Heston, W. D. Novel role of prostatespecific membrane antigen in suppressing prostate cancer invasiveness. Cancer Res, 2005, 65, 727-731. (Pubitemid 40216430)
63. Aggarwal, S.; Ricklis, R. M.; Williams, S. A.; Denmeade, S. R. Comparative study of PSMA expression in the prostate of mouse, dog, monkey, and human. Prostate, 2006, 66, 903-910. (Pubitemid 43849589)
64. Shafizadeh, T.B. and Halsted, C. H. gamma-Glutamyl hydrolase, not glutamate carboxypeptidase II, hydrolyzes dietary folate in rat small intestine. J. Nutr., 2007, 137, 1149-1153. (Pubitemid 46701903)
65. Su, S.L.; Huang, I. P.; Fair, W. R.; Powell, C. T.; Heston, W. D. Alternatively spliced variants of prostate-specific membrane antigen RNA: Ratio of expression as a potential measurement of progression. Cancer Res., 1995, 55, 1441-1443.
66. Schmittgen, T.D.; Teske, S.; Vessella, R. L.; True, L. D.; Zakrajsek, B. A. Expression of prostate specific membrane antigen and three alternatively spliced variants of PSMA in prostate cancer patients. Int. J. Cancer, 2003, 107, 323-329. (Pubitemid 37152918)
67. Grauer, L.S.; Lawler, K. D.; Marignac, J. L.; Kumar, A.; Goel, A. S.; Wolfert, R. L. Identification, purification, and subcellular localization of prostate-specific membrane antigen PSM' protein in the LNCaP prostatic carcinoma cell line. Cancer Res., 1998, 58, 4787-4789. (Pubitemid 28503668)
68. Mlcochova, P.; Barinka, C.; Tykvart, J.; Sacha, P.; Konvalinka, J. Prostatespecific membrane antigen and its truncated form PSM'. Prostate, 2009, 69, 471-479.
69. Bzdega, T.; Crowe, S. L.; Ramadan, E. R.; Sciarretta, K. H.; Olszewski, R. T.; Ojeifo, O. A.; Rafalski, V. A.; Wroblewska, B.; Neale, J. H. The cloning and characterization of a second brain enzyme with NAAG peptidase activity. J. Neurochem., 2004, 89, 627-635. (Pubitemid 38534148)
70. Pangalos, M.N.; Neefs, J. M.; Somers, M.; Verhasselt, P.; Bekkers, M.; van der, H. L.; Fraiponts, E.; Ashton, D.; Gordon, R. D. Isolation and expression of novel human glutamate carboxypeptidases with N-Acetylated alpha-linked acidic dipeptidase and dipeptidyl peptidase IV activity. J. Biol. Chem., 1999, 274, 8470-8483. (Pubitemid 29164636)
71. Bacich, D.J.; Ramadan, E.; O'Keefe, D. S.; Bukhari, N.; Wegorzewska, I.; Ojeifo, O.; Olszewski, R.; Wrenn, C. C.; Bzdega, T.; Wroblewska, B.; Heston, W. D.; Neale, J. H. Deletion of the glutamate carboxypeptidase II gene in mice reveals a second enzyme activity that hydrolyzes Nacetylaspartylglutamate. J. Neurochem., 2002, 83, 20-29.
72. Hlouchova, K.; Barinka, C.; Konvalinka, J.; Lubkowski, J. Structural insight into the evolutionary and pharmacologic homology of glutamate carboxypeptidases II and III. FEBS J., 2009, 276, 4448-4462.
73. Gingras, R.; Richard, C.; El-Alfy, M.; Morales, C. R.; Potier, M.; Pshezhetsky, A. V. Purification, cDNA cloning, and expression of a new human blood plasma glutamate carboxypeptidase homologous to N-Acetylaspartyl-Alpha- glutamate carboxypeptidase/prostate-specific membrane antigen. J. Biol. Chem., 1999, 274, 11742-11750.
74. Zajc, T.; Suban, D.; Rajkovic, J.; Dolenc, I. Baculoviral expression and characterization of human recombinant PGCP in the form of an active mature dimer and an inactive precursor protein. Protein Expr. Purif., 2011, 75, 119-126.
75. Luthi-Carter, R.; Barczak, A. K.; Speno, H.; Coyle, J. T. Hydrolysis of the neuropeptide N-Acetylaspartylglutamate (NAAG) by cloned human glutamate carboxypeptidase II. Brain Res., 1998, 795, 341-348. (Pubitemid 28337848)
76. Pinto, J.T.; Suffoletto, B. P.; Berzin, T. M.; Qiao, C. H.; Lin, S.; Tong, W. P.; May, F.; Mukherjee, B.; Heston, W. D. Prostate-specific membrane antigen: A novel folate hydrolase in human prostatic carcinoma cells. Clin. Cancer Res., 1996, 2, 1445-1451. (Pubitemid 126447436)
77. Robinson, M.B.; Blakely, R. D.; Couto, R.; Coyle, J. T. Hydrolysis of the brain dipeptide N-Acetyl-L-Aspartyl-L-glutamate. Identification and characterization of a novel N-Acetylated alpha-linked acidic dipeptidase activity from rat brain. J. Biol. Chem., 1987, 262, 14498-14506. (Pubitemid 17157357)
78. Rajasekaran, S.A.; Christiansen, J. J.; Schmid, I.; Oshima, E.; Ryazantsev, S.; Sakamoto, K.; Weinstein, J.; Rao, N. P.; Rajasekaran, A. K. Prostatespecific membrane antigen associates with anaphase-promoting complex and induces chromosomal instability. Mol. Cancer Ther., 2008, 7, 2142-2151.
79. Colombatti, M.; Grasso, S.; Porzia, A.; Fracasso, G.; Scupoli, M. T.; Cingarlini, S.; Poffe, O.; Naim, H. Y.; Heine, M.; Tridente, G.; Mainiero, F.; Ramarli, D. The prostate specific membrane antigen regulates the expression of IL-6 and CCL5 in prostate tumour cells by activating the MAPK pathways. PLoS. One., 2009, 4, e4608.
80. Zhao, R.; Matherly, L. H.; Goldman, I. D. Membrane transporters and folate homeostasis: Intestinal absorption and transport into systemic compartments and tissues. Expert. Rev. Mol. Med., 2009, 11, e4.
81. Halsted, C.H.; Ling, E. H.; Luthi-Carter, R.; Villanueva, J. A.; Gardner, J. M.; Coyle, J. T. Folylpoly-gamma-glutamate carboxypeptidase from pig jejunum. Molecular characterization and relation to glutamate carboxypeptidase II. J. Biol. Chem., 1998, 273, 20417-20424. (Pubitemid 28377608)
82. Devlin, A.M.; Ling, E. H.; Peerson, J. M.; Fernando, S.; Clarke, R.; Smith, A. D.; Halsted, C. H. Glutamate carboxypeptidase II: A polymorphism associated with lower levels of serum folate and hyperhomocysteinemia. Hum. Mol. Genet., 2000, 9, 2837-2844.
83. Afman, L.A.; Trijbels, F. J.; Blom, H. J. The H475Y polymorphism in the glutamate carboxypeptidase II gene increases plasma folate without affecting the risk for neural tube defects in humans. J. Nutr., 2003, 133, 75-77. (Pubitemid 36070580)
84. Devlin, A.M.; Clarke, R.; Birks, J.; Evans, J. G.; Halsted, C. H. Interactions among polymorphisms in folate-metabolizing genes and serum total homocysteine concentrations in a healthy elderly population. Am. J. Clin. Nutr., 2006, 83, 708-713. (Pubitemid 44699220)
85. Gotze, T.; Rocken, C.; Rohl, F. W.; Wex, T.; Hoffmann, J.; Westphal, S.; Malfertheiner, P.; Ebert, M. P.; Dierkes, J. Gene polymorphisms of folate metabolizing enzymes and the risk of gastric cancer. Cancer Lett., 2007, 251, 228-236. (Pubitemid 46669797)
86. Halsted, C.H.; Wong, D. H.; Peerson, J. M.; Warden, C. H.; Refsum, H.; Smith, A. D.; Nygard, O. K.; Ueland, P. M.; Vollset, S. E.; Tell, G. S. Relations of glutamate carboxypeptidase II (GCPII) polymorphisms to folate and homocysteine concentrations and to scores of cognition, anxiety, and depression in a homogeneous Norwegian population: The Hordaland Homocysteine Study. Am. J. Clin. Nutr., 2007, 86, 514-521. (Pubitemid 47256940)
87. Lievers, K.J.; Kluijtmans, L. A.; Boers, G. H.; Verhoef, P.; den, H. M.; Trijbels, F. J.; Blom, H. J. Influence of a glutamate carboxypeptidase II (GCPII) polymorphism (1561C→T) on plasma homocysteine, folate and vitamin B(12) levels and its relationship to cardiovascular disease risk. Atherosclerosis, 2002, 164, 269-273. (Pubitemid 35223076)
88. Morin, I.; Devlin, A. M.; Leclerc, D.; Sabbaghian, N.; Halsted, C. H.; Finnell, R.; Rozen, R. Evaluation of genetic variants in the reduced folate carrier and in glutamate carboxypeptidase II for spina bifida risk. Mol. Genet. Metab, 2003, 79, 197-200. (Pubitemid 36809047)
89. Coyle, J.T. The nagging question of the function of Nacetylaspartylglutamate. Neurobiol. Dis., 1997, 4, 231-238.
90. Neale, J.H.; Bzdega, T.; Wroblewska, B. N-Acetylaspartylglutamate: The most abundant peptide neurotransmitter in the mammalian central nervous system. J. Neurochem., 2000, 75, 443-452. (Pubitemid 30485424)
91. Becker, I.; Lodder, J.; Gieselmann, V.; Eckhardt, M. Molecular characterization of N-Acetylaspartylglutamate synthetase. J. Biol. Chem., 2010, 285, 29156-29164.
92. Tsai, G.; Forloni, G.; Robinson, M. B.; Stauch, B. L.; Coyle, J. T. Calciumdependent evoked release of N-[3H]acetylaspartylglutamate from the optic pathway. J. Neurochem., 1988, 51, 1956-1959. (Pubitemid 19010992)
93. Zollinger, M.; Amsler, U.; Do, K. Q.; Streit, P.; Cuenod, M. Release of Nacetylaspartylglutamate on depolarization of rat brain slices. J. Neurochem., 1988, 51, 1919-1923. (Pubitemid 19010984)
94. Wroblewska, B.; Wroblewski, J. T.; Pshenichkin, S.; Surin, A.; Sullivan, S. E.; Neale, J. H. N-Acetylaspartylglutamate selectively activates mGluR3 receptors in transfected cells. J. Neurochem., 1997, 69, 174-181. (Pubitemid 27274170)
95. Wroblewska, B.; Santi, M. R.; Neale, J. H. N-Acetylaspartylglutamate activates cyclic AMP-coupled metabotropic glutamate receptors in cerebellar astrocytes. Glia, 1998, 24, 172-179. (Pubitemid 28403995)
96. Wroblewska, B.; Wegorzewska, I. N.; Bzdega, T.; Olszewski, R. T.; Neale, J. H. Differential negative coupling of type 3 metabotropic glutamate receptor to cyclic GMP levels in neurons and astrocytes. J. Neurochem., 2006, 96, 1071-1077.
97. Bruno, V.; Battaglia, G.; Casabona, G.; Copani, A.; Caciagli, F.; Nicoletti, F. Neuroprotection by glial metabotropic glutamate receptors is mediated by transforming growth factor-beta. J. Neurosci., 1998, 18, 9594-9600. (Pubitemid 28543740)
98. Thomas, A.G.; Liu, W.; Olkowski, J. L.; Tang, Z.; Lin, Q.; Lu, X. C.; Slusher, B. S. Neuroprotection mediated by glutamate carboxypeptidase II (NAALADase) inhibition requires TGF-beta. Eur. J. Pharmacol., 2001, 430, 33-40. (Pubitemid 33042708)
99. Niswender, C.M. and Conn, P. J. Metabotropic glutamate receptors: Physiology, pharmacology, and disease. Annu. Rev. Pharmacol. Toxicol., 2010, 50, 295-322.
100. Baslow, M.H. Functions of N-Acetyl-L-Aspartate and N-Acetyl- Laspartylglutamate in the vertebrate brain: Role in glial cell-specific signaling. J. Neurochem., 2000, 75, 453-459. (Pubitemid 30485425)
101. Riveros, N. and Orrego, F. A study of possible excitatory effects of Nacetylaspartylglutamate in different in vivo and in vitro brain preparations. Brain Res., 1984, 299, 393-395. (Pubitemid 14112485)
102. Doble, A. The role of excitotoxicity in neurodegenerative disease: Implications for therapy. Pharmacol. Ther., 1999, 81, 163-221. (Pubitemid 29094735)
103. Lau, A. and Tymianski, M. Glutamate receptors, neurotoxicity and neurodegeneration. Pflugers Arch., 2010, 460, 525-542.
104. Gordon, P.H. Amyotrophic lateral sclerosis: Pathophysiology, diagnosis and management. CNS. Drugs, 2011, 25, 1-15.
105. Syed, T.U. and Sajatovic, M. Extended-release lamotrigine in the treatment of patients with epilepsy. Expert. Opin. Pharmacother., 2010, 11, 1579-1585.
106. Serval, V.; Galli, T.; Cheramy, A.; Glowinski, J.; Lavielle, S. In vitro and in vivo inhibition of N-Acetyl-L-Aspartyl-L-glutamate catabolism by N-Acylated L-glutamate analogs. J Pharmacol Exp Ther, 1992, 260, 1093-1100.
107. Subasinghe, N.; Schulte, M.; Chan, M. Y.; Roon, R. J.; Koerner, J. F.; Johnson, R. L. Synthesis of acyclic and dehydroaspartic acid analogues of Ac-Asp-Glu-OH and their inhibition of rat brain N-Acetylated alpha-linked acidic dipeptidase (NAALA dipeptidase). J. Med.Chem., 1990, 33, 2734-2744. (Pubitemid 20312136)
108. Jackson, P.F.; Cole, D. C.; Slusher, B. S.; Stetz, S. L.; Ross, L. E.; Donzanti, B. A.; Trainor, D. A. Design, synthesis, and biological activity of a potent inhibitor of the neuropeptidase N-Acetylated alpha-linked acidic dipeptidase. J. Med. Chem., 1996, 39, 619-622. (Pubitemid 26041474)
109. Slusher, B.S.; Vornov, J. J.; Thomas, A. G.; Hurn, P. D.; Harukuni, I.; Bhardwaj, A.; Traystman, R. J.; Robinson, M. B.; Britton, P.; Lu, X. C.; Tortella, F. C.; Wozniak, K. M.; Yudkoff, M.; Potter, B. M.; Jackson, P. F. Selective inhibition of NAALADase, which converts NAAG to glutamate, reduces ischemic brain injury. Nat. Med., 1999, 5, 1396-1402.
110. Jackson, P.F. and Slusher, B. S. Design of NAALADase inhibitors: A novel neuroprotective strategy. Curr Med Chem, 2001, 8, 949-957. (Pubitemid 32633553)
111. Ding, P.; Miller, M. J.; Chen, Y.; Helquist, P.; Oliver, A. J.; Wiest, O. Syntheses of conformationally constricted molecules as potential NAALADase/PSMA inhibitors. Org. Lett., 2004, 6, 1805-1808. (Pubitemid 38748322)
112. Cai, Y.; Qiu, Y.; Wei, L.; Zhang, W.; Hu, S.; Smith, P. R.; Crabtree, V. P.; Tong, S.; Thakor, N. V.; Zhu, Y. Complex character analysis of heart rate variability following brain asphyxia. Med Eng Phys, 2006, 28, 297-303.
113. Cai, Z.; Lin, S.; Rhodes, P. G. Neuroprotective effects of Nacetylaspartylglutamate in a neonatal rat model of hypoxia-ischemia. Eur J Pharmacol, 2002, 437, 139-145. (Pubitemid 34219474)
114. Harada, C.; Harada, T.; Slusher, B. S.; Yoshida, K.; Matsuda, H.; Wada, K. N-Acetylated-Alpha-linked-Acidic dipeptidase inhibitor has a neuroprotective effect on mouse retinal ganglion cells after pressure-induced ischemia. Neurosci Lett, 2000, 292, 134-136.
115. Long, J.B.; Yourick, D. L.; Slusher, B. S.; Robinson, M. B.; Meyerhoff, J. L. Inhibition of glutamate carboxypeptidase II (NAALADase) protects against dynorphin A-induced ischemic spinal cord injury in rats. Eur J Pharmacol, 2005, 508, 115-122. (Pubitemid 40169909)
116. Chen, S.R.; Wozniak, K. M.; Slusher, B. S.; Pan, H. L. Effect of 2-(phosphono-methyl)-pentanedioic acid on allodynia and afferent ectopic discharges in a rat model of neuropathic pain. J. Pharmacol. Exp. Ther., 2002, 300, 662-667.
117. Yamamoto, T.; Nozaki-Taguchi, N.; Sakashita, Y. Spinal N-Acetyl-Alphalinked acidic dipeptidase (NAALADase) inhibition attenuates mechanical allodynia induced by paw carrageenan injection in the rat. Brain Res., 2001, 909, 138-144. (Pubitemid 32710127)
118. Yamamoto, T.; Nozaki-Taguchi, N.; Sakashita, Y.; Inagaki, T. Inhibition of spinal N-Acetylated-Alpha-linked acidic dipeptidase produces an antinociceptive effect in the rat formalin test. Neuroscience, 2001, 102, 473-479. (Pubitemid 32126501)
119. Thomas, A.G.; Corse, A. M.; Coccia, C. F.; Bilak, M. M.; Rothstein, J. D.; Slusher, B. S. NAALADase inhibition protects motor neurons against chronic glutamate toxicity. Eur. J Pharmacol., 2003, 471, 177-184. (Pubitemid 36776412)
120. Luszczki, J.J.; Mohamed, M.; Czuczwar, S. J. 2- phosphonomethylpentanedioic acid (glutamate carboxypeptidase II inhibitor) increases threshold for electroconvulsions and enhances the antiseizure action of valproate against maximal electroshock-induced seizures in mice. Eur J Pharmacol, 2006, 531, 66-73. (Pubitemid 43202217)
121. Witkin, J.M.; Gasior, M.; Schad, C.; Zapata, A.; Shippenberg, T.; Hartman, T.; Slusher, B. S. NAALADase (GCP II) inhibition prevents cocaine-kindled seizures. Neuropharmacology, 2002, 43, 348-356. (Pubitemid 35257926)
122. Popik, P.; Kozela, E.; Wrobel, M.; Wozniak, K. M.; Slusher, B. S. Morphine tolerance and reward but not expression of morphine dependence are inhibited by the selective glutamate carboxypeptidase II (GCP II, NAALADase) inhibitor, 2-PMPA. Neuropsychopharmacology, 2003, 28, 457-467.
123. Lumley, L.A.; Robison, C. L.; Slusher, B. S.; Wozniak, K.; Dawood, M.; Meyerhoff, J. L. Reduced isolation-induced aggressiveness in mice following NAALADase inhibition. Psychopharmacology (Berl), 2004, 171, 375-381. (Pubitemid 38200048)
124. Hecker, S.J. and Erion, M. D. Prodrugs of phosphates and phosphonates. J. Med. Chem., 2008, 51, 2328-2345. (Pubitemid 351628494)
125. Majer, P.; Jackson, P. F.; Delahanty, G.; Grella, B. S.; Ko, Y. S.; Li, W.; Liu, Q.; Maclin, K. M.; Polakova, J.; Shaffer, K. A.; Stoermer, D.; Vitharana, D.; Wang, E. Y.; Zakrzewski, A.; Rojas, C.; Slusher, B. S.; Wozniak, K. M.; Burak, E.; Limsakun, T.; Tsukamoto, T. Synthesis and biological evaluation of thiol-based inhibitors of glutamate carboxypeptidase II: Discovery of an orally active GCP II inhibitor. J Med. Chem., 2003, 46, 1989-1996. (Pubitemid 36532241)
126. Ghadge, G.D.; Slusher, B. S.; Bodner, A.; Canto, M. D.; Wozniak, K.; Thomas, A. G.; Rojas, C.; Tsukamoto, T.; Majer, P.; Miller, R. J.; Monti, A. L.; Roos, R. P. Glutamate carboxypeptidase II inhibition protects motor neurons from death in familial amyotrophic lateral sclerosis models. Proc. Natl. Acad. Sci. U. S. A, 2003, 100, 9554-9559. (Pubitemid 37033966)
127. Zhang, W.; Murakawa, Y.; Wozniak, K. M.; Slusher, B.; Sima, A. A. The preventive and therapeutic effects of GCPII (NAALADase) inhibition on painful and sensory diabetic neuropathy. J Neurol Sci, 2006, 247, 217-223. (Pubitemid 44301265)
128. Slusher, B.S.; Thomas, A.; Paul, M.; Schad, C. A.; Ashby, C. R., Jr. Expression and acquisition of the conditioned place preference response to cocaine in rats is blocked by selective inhibitors of the enzyme N-Acetylatedalpha-linked-Acidic dipeptidase (NAALADASE). Synapse, 2001, 41, 22-28. (Pubitemid 32467476)
129. Grella, B.; Adams, J.; Berry, J. F.; Delahanty, G.; Ferraris, D. V.; Majer, P.; Ni, C.; Shukla, K.; Shuler, S. A.; Slusher, B. S.; Stathis, M.; Tsukamoto, T. The discovery and structure-Activity relationships of indole-based inhibitors of glutamate carboxypeptidase II. Bioorg Med Chem Lett, 2010, 20, 7222-7225.
130. Barinka, C.; Byun, Y.; Dusich, C. L.; Banerjee, S. R.; Chen, Y.; Castanares, M.; Kozikowski, A. P.; Mease, R. C.; Pomper, M. G.; Lubkowski, J. Interactions between human glutamate carboxypeptidase II and urea-based inhibitors: Structural characterization. J. Med. Chem., 2008, 51, 7737-7743.
131. Kozikowski, A.P.; Nan, F.; Conti, P.; Zhang, J.; Ramadan, E.; Bzdega, T.; Wroblewska, B.; Neale, J. H.; Pshenichkin, S.; Wroblewski, J. T. Design of remarkably simple, yet potent urea-based inhibitors of glutamate carboxypeptidase II (NAALADase). J. Med.Chem., 2001, 44, 298-301. (Pubitemid 32113579)
132. Olszewski, R.T.; Bukhari, N.; Zhou, J.; Kozikowski, A. P.; Wroblewski, J. T.; Shamimi-Noori, S.; Wroblewska, B.; Bzdega, T.; Vicini, S.; Barton, F. B.; Neale, J. H. NAAG peptidase inhibition reduces locomotor activity and some stereotypes in the PCP model of schizophrenia via group II mGluR. J Neurochem, 2004, 89, 876-885. (Pubitemid 38684735)
133. Zhong, C.; Zhao, X.; Sarva, J.; Kozikowski, A.; Neale, J. H.; Lyeth, B. G. NAAG peptidase inhibitor reduces acute neuronal degeneration and astrocyte damage following lateral fluid percussion TBI in rats. J Neurotrauma, 2005, 22, 266-276. (Pubitemid 40333520)
134. Yamamoto, T.; Hirasawa, S.; Wroblewska, B.; Grajkowska, E.; Zhou, J.; Kozikowski, A.; Wroblewski, J.; Neale, J. H. Antinociceptive effects of Nacetylaspartylglutamate (NAAG) peptidase inhibitors ZJ-11, ZJ-17 and ZJ-43 in the rat formalin test and in the rat neuropathic pain model. Eur J Neurosci, 2004, 20, 483-494. (Pubitemid 38969633)
135. Yamamoto, T.; Saito, O.; Aoe, T.; Bartolozzi, A.; Sarva, J.; Zhou, J.; Kozikowski, A.; Wroblewska, B.; Bzdega, T.; Neale, J. H. Local administration of N-Acetylaspartylglutamate (NAAG) peptidase inhibitors is analgesic in peripheral pain in rats. Eur J Neurosci, 2007, 25, 147-158. (Pubitemid 46098894)
136. Harsanyi, K.; Domany, G.; Greiner, I.; Forintos, H.; Keglevich, G. Synthesis of 2-phosphinoxidomethyl-And 2-phosphonomethyl glutaric acid derivatives. Heteroatom Chemistry, 2005, 16, 562-565. (Pubitemid 43082166)
137. Stoermer, D.; Liu, Q.; Hall, M. R.; Flanary, J. M.; Thomas, A. G.; Rojas, C.; Slusher, B. S.; Tsukamoto, T. Synthesis and biological evaluation of hydroxamate-Based inhibitors of glutamate carboxypeptidase II. Bioorg. Med. Chem. Lett., 2003, 13, 2097-2100. (Pubitemid 36694282)
138. Adedoyin, M.O.; Vicini, S.; Neale, J. H. Endogenous Nacetylaspartylglutamate (NAAG) inhibits synaptic plasticity/transmission in the amygdala in a mouse inflammatory pain model. Mol Pain, 2010, 6, 60.
139. Carpenter, K.J.; Sen, S.; Matthews, E. A.; Flatters, S. L.; Wozniak, K. M.; Slusher, B. S.; Dickenson, A. H. Effects of GCP-II inhibition on responses of dorsal horn neurones after inflammation and neuropathy: An electrophysiological study in the rat. Neuropeptides, 2003, 37, 298-306. (Pubitemid 37464033)
140. Majer, P.; Jackson, P. F.; Delahanty, G.; Grella, B. S.; Ko, Y. S.; Li, W.; Liu, Q.; Maclin, K. M.; Polakova, J.; Shaffer, K. A.; Stoermer, D.; Vitharana, D.; Wang, E. Y.; Zakrzewski, A.; Rojas, C.; Slusher, B. S.; Wozniak, K. M.; Burak, E.; Limsakun, T.; Tsukamoto, T. Synthesis and biological evaluation of thiol-based inhibitors of glutamate carboxypeptidase II: Discovery of an orally active GCP II inhibitor. J. Med. Chem., 2003, 46, 1989-1996. (Pubitemid 36532241)
141. Nagel, J.; Belozertseva, I.; Greco, S.; Kashkin, V.; Malyshkin, A.; Jirgensons, A.; Shekunova, E.; Eilbacher, B.; Bespalov, A.; Danysz, W. Effects of NAAG peptidase inhibitor 2-PMPA in model chronic pain -relation to brain concentration. Neuropharmacology, 2006, 51, 1163-1171. (Pubitemid 44715967)
142. Sasson, N.J.; Turner-Brown, L. M.; Holtzclaw, T. N.; Lam, K. S.; Bodfish, J. W. Children with autism demonstrate circumscribed attention during passive viewing of complex social and nonsocial picture arrays. Autism Res, 2008, 1, 31-42.
143. Yamamoto, T.; Kozikowski, A.; Zhou, J.; Neale, J. H. Intracerebroventricular administration of N-Acetylaspartylglutamate (NAAG) peptidase inhibitors is analgesic in inflammatory pain. Mol Pain, 2008, 4, 31.
144. Zhang, W.; Slusher, B.; Murakawa, Y.; Wozniak, K. M.; Tsukamoto, T.; Jackson, P. F.; Sima, A. A. GCPII (NAALADase) inhibition prevents longterm diabetic neuropathy in type 1 diabetic BB/Wor rats. J Neurol Sci, 2002, 194, 21-28. (Pubitemid 34051551)
145. Saito, O.; Aoe, T.; Kozikowski, A.; Sarva, J.; Neale, J. H.; Yamamoto, T. Ketamine and N-Acetylaspartylglutamate peptidase inhibitor exert analgesia in bone cancer pain. Can J Anaesth, 2006, 53, 891-898. (Pubitemid 44696513)
146. Tortella, F.C.; Lin, Y.; Ved, H.; Slusher, B. S.; Dave, J. R. Neuroprotection produced by the NAALADase inhibitor 2-PMPA in rat cerebellar neurons. Eur J Pharmacol, 2000, 402, 31-37. (Pubitemid 30625307)
147. Williams, A.J.; Lu, X. M.; Slusher, B.; Tortella, F. C. Electroencephalogram analysis and neuroprotective profile of the N-Acetylated-Alpha-linked acidic dipeptidase inhibitor, GPI5232, in normal and brain-injured rats. J. Pharmacol. Exp. Ther., 2001, 299, 48-57. (Pubitemid 32905117)
148. Ghadge, G.D.; Slusher, B. S.; Bodner, A.; Canto, M. D.; Wozniak, K.; Thomas, A. G.; Rojas, C.; Tsukamoto, T.; Majer, P.; Miller, R. J.; Monti, A. L.; Roos, R. P. Glutamate carboxypeptidase II inhibition protects motor neurons from death in familial amyotrophic lateral sclerosis models. Proc. Natl. Acad. Sci. U S A, 2003, 100, 9554-9559. (Pubitemid 37033966)
149. Zhong, C.; Zhao, X.; Van, K. C.; Bzdega, T.; Smyth, A.; Zhou, J.; Kozikowski, A. P.; Jiang, J.; O'Connor W, T.; Berman, R. F.; Neale, J. H.; Lyeth, B. G. NAAG peptidase inhibitor increases dialysate NAAG and reduces glutamate, aspartate and GABA levels in the dorsal hippocampus following fluid percussion injury in the rat. J Neurochem, 2006, 97, 1015-1025.
150. Berent-Spillson, A.; Robinson, A. M.; Golovoy, D.; Slusher, B.; Rojas, C.; Russell, J. W. Protection against glucose-induced neuronal death by NAAG and GCP II inhibition is regulated by mGluR3. J Neurochem, 2004, 89, 90-99. (Pubitemid 38420677)
151. Carozzi, V.A.; Chiorazzi, A.; Canta, A.; Lapidus, R. G.; Slusher, B. S.; Wozniak, K. M.; Cavaletti, G. Glutamate carboxypeptidase inhibition reduces the severity of chemotherapy-induced peripheral neurotoxicity in rat. Neurotox Res, 17, 380-391.
152. McKinzie, D.L.; Li, T. K.; McBride, W. J.; Slusher, B. S. NAALADase inhibition reduces alcohol consumption in the alcohol-preferring (P) line of rats. Addict. Biol., 2000, 5, 411-416.
153. Kozela, E.; Wrobel, M.; Kos, T.; Wojcikowski, J.; Daniel, W. A.; Wozniak, K. M.; Slusher, B. S.; Popik, P. 2-MPPA, a selective glutamate carboxypeptidase II inhibitor, attenuates morphine tolerance but not dependence in C57/Bl mice. Psychopharmacology (Berl), 2005, 183, 275-284. (Pubitemid 41660412)
154. Peng, X.Q.; Li, J.; Gardner, E. L.; Ashby, C. R., Jr.; Thomas, A.; Wozniak, K.; Slusher, B. S.; Xi, Z. X. Oral administration of the NAALADase inhibitor GPI-5693 attenuates cocaine-induced reinstatement of drug-seeking behavior in rats. Eur J Pharmacol, 627, 156-161.
155. Shippenberg, T.S.; Rea, W.; Slusher, B. S. Modulation of behavioral sensitization to cocaine by NAALADase inhibition. Synapse, 2000, 38, 161-166.
156. Xi, Z.X.; Kiyatkin, M.; Li, X.; Peng, X. Q.; Wiggins, A.; Spiller, K.; Li, J.; Gardner, E. L. N-Acetylaspartylglutamate (NAAG) inhibits intravenous cocaine self-Administration and cocaine-enhanced brain-stimulation reward in rats. Neuropharmacology, 58, 304-313.
157. Xi, Z.X.; Li, X.; Peng, X. Q.; Li, J.; Chun, L.; Gardner, E. L.; Thomas, A. G.; Slusher, B. S.; Ashby, C. R., Jr. Inhibition of NAALADase by 2-PMPA attenuates cocaine-induced relapse in rats: A NAAG-mGluR2/3-mediated mechanism. J Neurochem, 112, 564-576.
158. Bacich, D.J.; Wozniak, K. M.; Lu, X. C.; O'Keefe, D. S.; Callizot, N.; Heston, W. D.; Slusher, B. S. Mice lacking glutamate carboxypeptidase II are protected from peripheral neuropathy and ischemic brain injury. J Neurochem, 2005, 95, 314-323. (Pubitemid 41457500)
159. Low, S.J. and Roland, C. L. Review of NMDA antagonist-induced neurotoxicity and implications for clinical development. Int J Clin Pharmacol Ther, 2004, 42, 1-14. (Pubitemid 38100854)
160. Carroll, P.R.; Coakley, F. V.; Kurhanewicz, J. Magnetic resonance imaging and spectroscopy of prostate cancer. Rev. Urol., 2006, 8 Suppl 1, S4-S10.
161. Hricak, H.; Choyke, P. L.; Eberhardt, S. C.; Leibel, S. A.; Scardino, P. T. Imaging prostate cancer: A multidisciplinary perspective. Radiology, 2007, 243, 28-53. (Pubitemid 46579693)
162. Jadvar, H. Molecular imaging of prostate cancer with 18Ffluorodeoxyglucose PET. Nat. Rev. Urol., 2009, 6, 317-323.
163. Mease, R.C. Radionuclide based imaging of prostate cancer. Curr. Top. Med. Chem., 2010, 10, 1600-1616.
164. Zaheer, A.; Cho, S. Y.; Pomper, M. G. New agents and techniques for imaging prostate cancer. J. Nucl. Med., 2009, 50, 1387-1390.
165. Iagaru, A.; Mittra, E.; Dick, D. W.; Gambhir, S. S. Prospective Evaluation of (99m)Tc MDP Scintigraphy, (18)F NaF PET/CT, and (18)F FDG PET/CT for Detection of Skeletal Metastases. Mol. Imaging Biol., 2011, in press.
166. Igerc, I.; Kohlfurst, S.; Gallowitsch, H. J.; Matschnig, S.; Kresnik, E.; Gomez-Segovia, I.; Lind, P. The value of 18F-choline PET/CT in patients with elevated PSA-level and negative prostate needle biopsy for localisation of prostate cancer. Eur. J. Nucl. Med. Mol. Imaging, 2008, 35, 976-983.
167. Reske, S.N.; Blumstein, N. M.; Glatting, G. [11C]choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy. Eur. J. Nucl. Med. Mol. Imaging, 2008, 35, 9-17. (Pubitemid 350234137)
168. Schuster, D.M.; Votaw, J. R.; Nieh, P. T.; Yu, W.; Nye, J. A.; Master, V.; Bowman, F. D.; Issa, M. M.; Goodman, M. M. Initial experience with the radiotracer anti-1-Amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma. J. Nucl. Med., 2007, 48, 56-63. (Pubitemid 47555376)
169. Tehrani, O.S.; Muzik, O.; Heilbrun, L. K.; Douglas, K. A.; Lawhorn-Crews, J. M.; Sun, H.; Mangner, T. J.; Shields, A. F. Tumor imaging using 1-(2'-deoxy-2'-18F-fluoro-beta-D-Arabinofuranosyl)thymine and PET. J. Nucl. Med., 2007, 48, 1436-1441. (Pubitemid 47397393)
170. Dehdashti, F.; Picus, J.; Michalski, J. M.; Dence, C. S.; Siegel, B. A.; Katzenellenbogen, J. A.; Welch, M. J. Positron tomographic assessment of androgen receptors in prostatic carcinoma. Eur. J. Nucl. Med. Mol. Imaging, 2005, 32, 344-350. (Pubitemid 40562127)
171. Larson, S.M.; Morris, M.; Gunther, I.; Beattie, B.; Humm, J. L.; Akhurst, T. A.; Finn, R. D.; Erdi, Y.; Pentlow, K.; Dyke, J.; Squire, O.; Bornmann, W.; McCarthy, T.; Welch, M.; Scher, H. Tumor localization of 16beta-18Ffluoro- 5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer. J. Nucl. Med., 2004, 45, 366-373. (Pubitemid 47618608)
172. Bander, N.H.; Nanus, D. M.; Milowsky, M. I.; Kostakoglu, L.; Vallabahajosula, S.; Goldsmith, S. J. Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen. Semin. Oncol., 2003, 30, 667-676.
173. Banerjee, S.R.; Foss, C. A.; Castanares, M.; Mease, R. C.; Byun, Y.; Fox, J. J.; Hilton, J.; Lupold, S. E.; Kozikowski, A. P.; Pomper, M. G. Synthesis and evaluation of technetium-99m-And rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA). J. Med. Chem., 2008, 51, 4504-4517.
174. Pomper, M.G.; Musachio, J. L.; Zhang, J.; Scheffel, U.; Zhou, Y.; Hilton, J.; Maini, A.; Dannals, R. F.; Wong, D. F.; Kozikowski, A. P. 11C-MCG: Synthesis, uptake selectivity, and primate PET of a probe for glutamate carboxypeptidase II (NAALADase). Mol. Imaging, 2002, 1, 96-101.
175. Lapi, S.E.; Wahnishe, H.; Pham, D.; Wu, L. Y.; Nedrow-Byers, J. R.; Liu, T.; Vejdani, K.; VanBrocklin, H. F.; Berkman, C. E.; Jones, E. F. Assessment of an 18F-labeled phosphoramidate peptidomimetic as a new prostate-specific membrane antigen-targeted imaging agent for prostate cancer. J. Nucl. Med., 2009, 50, 2042-2048.
176. Kularatne, S.A.; Zhou, Z.; Yang, J.; Post, C. B.; Low, P. S. Design, synthesis, and preclinical evaluation of prostate-specific membrane antigen targeted (99m)Tc-radioimaging agents. Mol. Pharm., 2009, 6, 790-800.
177. Murphy, G.P.; Maguire, R. T.; Rogers, B.; Partin, A. W.; Nelp, W. B.; Troychak, M. J.; Ragde, H.; Kenny, G. M.; Barren, R. J., III; Bowes, V. A.; Gregorakis, A. K.; Holmes, E. H.; Boynton, A. L. Comparison of serum PSMA, PSA levels with results of Cytogen-356 ProstaScint scanning in prostatic cancer patients. Prostate, 1997, 33, 281-285. (Pubitemid 27524708)
178. Nagda, S.N.; Mohideen, N.; Lo, S. S.; Khan, U.; Dillehay, G.; Wagner, R.; Campbell, S.; Flanigan, R. Long-term follow-up of 111In-capromab pendetide (ProstaScint) scan as pretreatment assessment in patients who undergo salvage radiotherapy for rising prostate-specific antigen after radical prostatectomy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys., 2007, 67, 834-840. (Pubitemid 46215867)
179. Wilkinson, S. and Chodak, G. The role of 111indium-capromab pendetide imaging for assessing biochemical failure after radical prostatectomy. J. Urol., 2004, 172, 133-136. (Pubitemid 41615054)
180. Smith-Jones, P.M.; Vallabhajosula, S.; Navarro, V.; Bastidas, D.; Goldsmith, S. J.; Bander, N. H. Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: Preclinical studies in nude mice bearing LNCaP human prostate tumor. J. Nucl. Med., 2003, 44, 610-617. (Pubitemid 40003748)
181. Yao, D.; Trabulsi, E. J.; Kostakoglu, L.; Vallabhajosula, S.; Joyce, M. A.; Nanus, D. M.; Milowsky, M.; Liu, H.; Goldsmith, S. J. The utility of monoclonal antibodies in the imaging of prostate cancer. Semin. Urol. Oncol., 2002, 20, 211-218. (Pubitemid 35001524)
182. Bander, N.H.; Milowsky, M. I.; Nanus, D. M.; Kostakoglu, L.; Vallabhajosula, S.; Goldsmith, S. J. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol, 2005, 23, 4591-4601. (Pubitemid 46224061)
183. McDevitt, M.R.; Barendswaard, E.; Ma, D.; Lai, L.; Curcio, M. J.; Sgouros, G.; Ballangrud, A. M.; Yang, W. H.; Finn, R. D.; Pellegrini, V.; Geerlings, M. W., Jr.; Lee, M.; Brechbiel, M. W.; Bander, N. H.; Cordon-Cardo, C.; Scheinberg, D. A. An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer. Cancer Res., 2000, 60, 6095-6100.
184. Pandit-Taskar, N.; O'Donoghue, J. A.; Morris, M. J.; Wills, E. A.; Schwartz, L. H.; Gonen, M.; Scher, H. I.; Larson, S. M.; Divgi, C. R. Antibody mass escalation study in patients with castration-resistant prostate cancer using 111In-J591: Lesion detectability and dosimetric projections for 90Y radioimmunotherapy. J. Nucl. Med., 2008, 49, 1066-1074. (Pubitemid 351948014)
185. Smith-Jones, P.M.; Vallabahajosula, S.; Goldsmith, S. J.; Navarro, V.; Hunter, C. J.; Bastidas, D.; Bander, N. H. In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. Cancer Res., 2000, 60, 5237-5243.
186. Vallabhajosula, S.; Smith-Jones, P. M.; Navarro, V.; Goldsmith, S. J.; Bander, N. H. Radioimmunotherapy of prostate cancer in human xenografts using monoclonal antibodies specific to prostate specific membrane antigen (PSMA): Studies in nude mice. Prostate, 2004, 58, 145-155. (Pubitemid 38160901)
187. Vallabhajosula, S.; Goldsmith, S. J.; Kostakoglu, L.; Milowsky, M. I.; Nanus, D. M.; Bander, N. H. Radioimmunotherapy of prostate cancer using 90Y-And 177Lu-labeled J591 monoclonal antibodies: Effect of multiple treatments on myelotoxicity. Clin. Cancer Res., 2005, 11, 7195-7200.
188. Vallabhajosula, S.; Goldsmith, S. J.; Hamacher, K. A.; Kostakoglu, L.; Konishi, S.; Milowski, M. I.; Nanus, D. M.; Bander, N. H. Prediction of myelotoxicity based on bone marrow radiation-Absorbed dose: Radioimmunotherapy studies using 90Y-And 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen. J. Nucl. Med., 2005, 46, 850-858.
189. Vallabhajosula, S.; Kuji, I.; Hamacher, K. A.; Konishi, S.; Kostakoglu, L.; Kothari, P. A.; Milowski, M. I.; Nanus, D. M.; Bander, N. H.; Goldsmith, S. J. Pharmacokinetics and biodistribution of 111In-And 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: Prediction of 90YJ591 radiation dosimetry based on 111In or 177Lu? J. Nucl. Med., 2005, 46, 634-641. (Pubitemid 41716408)
190. Holland, J.P.; Divilov, V.; Bander, N. H.; Smith-Jones, P. M.; Larson, S. M.; Lewis, J. S. 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo. J. Nucl. Med., 2010, 51, 1293-1300.
191. Alt, K.; Wiehr, S.; Ehrlichmann, W.; Reischl, G.; Wolf, P.; Pichler, B. J.; Elsasser-Beile, U.; Buhler, P. High-resolution animal PET imaging of prostate cancer xenografts with three different 64Cu-labeled antibodies against native cell-Adherent PSMA. Prostate, 2010, 70, 1413-1421.
192. Elsasser-Beile, U.; Reischl, G.; Wiehr, S.; Buhler, P.; Wolf, P.; Alt, K.; Shively, J.; Judenhofer, M. S.; Machulla, H. J.; Pichler, B. J. PET imaging of prostate cancer xenografts with a highly specific antibody against the prostate-specific membrane antigen. J. Nucl. Med., 2009, 50, 606-611.
193. Wolf, P.; Freudenberg, N.; Buhler, P.; Alt, K.; Schultze-Seemann, W.; Wetterauer, U.; Elsasser-Beile, U. Three conformational antibodies specific for different PSMA epitopes are promising diagnostic and therapeutic tools for prostate cancer. Prostate, 2010, 70, 562-569.
194. Javier, D.J.; Nitin, N.; Levy, M.; Ellington, A.; Richards-Kortum, R. Aptamer-targeted gold nanoparticles as molecular-specific contrast agents for reflectance imaging. Bioconjug. Chem., 2008, 19, 1309-1312. (Pubitemid 351874954)
195. Rockey, W.M.; Huang, L.; Kloepping, K. C.; Baumhover, N. J.; Giangrande, P. H.; Schultz, M. K. Synthesis and radiolabeling of chelator-RNA aptamer bioconjugates with copper-64 for targeted molecular imaging. Bioorg. Med. Chem., 2011, 19, 4080-4090.
196. Liu, T.; Wu, L. Y.; Kazak, M.; Berkman, C. E. Cell-Surface labeling and internalization by a fluorescent inhibitor of prostate-specific membrane antigen. Prostate, 2008, 68, 955-964. (Pubitemid 351794160)
197. Banerjee, S.R.; Pullambhatla, M.; Byun, Y.; Nimmagadda, S.; Green, G.; Fox, J. J.; Horti, A.; Mease, R. C.; Pomper, M. G. 68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer. J. Med. Chem., 2010, 53, 5333-5341.
198. Hillier, S.M.; Maresca, K. P.; Femia, F. J.; Marquis, J. C.; Foss, C. A.; Nguyen, N.; Zimmerman, C. N.; Barrett, J. A.; Eckelman, W. C.; Pomper, M. G.; Joyal, J. L.; Babich, J. W. Preclinical evaluation of novel glutamateurea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. Cancer Res., 2009, 69, 6932-6940.
199. Guilarte, T.R.; Hammoud, D. A.; McGlothan, J. L.; Caffo, B. S.; Foss, C. A.; Kozikowski, A. P.; Pomper, M. G. Dysregulation of glutamate carboxypeptidase II in psychiatric disease. Schizophr. Res., 2008, 99, 324-332.
200. Deb, N.; Goris, M.; Trisler, K.; Fowler, S.; Saal, J.; Ning, S.; Becker, M.; Marquez, C.; Knox, S. Treatment of hormone-refractory prostate cancer with 90Y-CYT-356 monoclonal antibody. Clin Cancer Res, 1996, 2, 1289-1297. (Pubitemid 26299426)
201. Henry, M.D.; Wen, S.; Silva, M. D.; Chandra, S.; Milton, M.; Worland, P. J. A prostate-specific membrane antigen-targeted monoclonal antibodychemotherapeutic conjugate designed for the treatment of prostate cancer. Cancer Res., 2004, 64, 7995-8001. (Pubitemid 39446934)
202. Huang, X.; Bennett, M.; Thorpe, P. E. Anti-tumor effects and lack of side effects in mice of an immunotoxin directed against human and mouse prostate-specific membrane antigen. Prostate, 2004, 61, 1-11. (Pubitemid 39095691)
203. Ma, J.Y.; Medicherla, S.; Kerr, I.; Mangadu, R.; Protter, A. A.; Higgins, L. S. Selective p38alpha mitogen-Activated protein kinase inhibitor attenuates lung inflammation and fibrosis in IL-13 transgenic mouse model of asthma. J Asthma Allergy, 2008, 1, 31-44.
204. Russell, P.J.; Hewish, D.; Carter, T.; Sterling-Levis, K.; Ow, K.; Hattarki, M.; Doughty, L.; Guthrie, R.; Shapira, D.; Molloy, P. L.; Werkmeister, J. A.; Kortt, A. A. Cytotoxic properties of immunoconjugates containing melittinlike peptide 101 against prostate cancer: In vitro and in vivo studies. Cancer Immunol. Immunother., 2004, 53, 411-421. (Pubitemid 38657254)
205. Wolf, P.; Alt, K.; Buhler, P.; Katzenwadel, A.; Wetterauer, U.; Tacke, M.; Elsasser-Beile, U. Anti-PSMA immunotoxin as novel treatment for prostate cancer? High and specific antitumor activity on human prostate xenograft tumors in SCID mice. Prostate, 2008, 68, 129-138. (Pubitemid 351186225)
206. Wolf, P.; Alt, K.; Wetterauer, D.; Buhler, P.; Gierschner, D.; Katzenwadel, A.; Wetterauer, U.; Elsasser-Beile, U. Preclinical evaluation of a recombinant anti-prostate specific membrane antigen single-chain immunotoxin against prostate cancer. J. Immunother., 2010, 33, 262-271.
207. Gao, X.; Cui, Y.; Levenson, R. M.; Chung, L. W.; Nie, S. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat. Biotechnol., 2004, 22, 969-976. (Pubitemid 39014473)
208. Sanna, V.; Pintus, G.; Roggio, A. M.; Punzoni, S.; Posadino, A. M.; Arca, A.; Marceddu, S.; Bandiera, P.; Uzzau, S.; Sechi, M. Targeted biocompatible nanoparticles for the delivery of (-)-epigallocatechin 3-gallate to prostate cancer cells. J. Med. Chem., 2011, 54, 1321-1332.
209. Yu, M.K.; Kim, D.; Lee, I. H.; So, J. S.; Jeong, Y. Y.; Jon, S. Image-Guided Prostate Cancer Therapy Using Aptamer-Functionalized Thermally Cross-Linked Superparamagnetic Iron Oxide Nanoparticles. Small, 2011, 7, 2241-2249.
210. Dhar, S.; Gu, F. X.; Langer, R.; Farokhzad, O. C.; Lippard, S. J. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc. Natl. Acad. Sci. U. S. A, 2008, 105, 17356-17361.
211. Murelli, R.P.; Zhang, A. X.; Michel, J.; Jorgensen, W. L.; Spiegel, D. A. Chemical control over immune recognition: A class of antibody-recruiting small molecules that target prostate cancer. J. Am. Chem. Soc., 2009, 131, 17090-17092.